Product Information

EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is a generic product labeled by NorthStar Rx LLC, priced at $0.5290 per EA under NDC 16714053401. Its NADAC has been published 213 times since Sep 7, 2022.

FDA first approved this application on May 15, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB

Emtricitabine and tenofovir disoproxil fumarate
$0.5290per EA

Strength

200; 300 mg/1; mg/1

Manufacturer

NorthStar Rx LLC

NDC

16714053401

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

9/23/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA203442

FDA Approved

5/15/2020

TE Code

AB

On Market Since

3/9/2022

Price Statistics

The NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has been published 213 times since Sep 7, 2022, and over the history we have for it it has declined 13.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.5290 per EA
All-time high$0.6267 (Jun 14, 2023)
All-time low$0.4258 (May 22, 2024)
52-week high$0.5867
52-week low$0.4508
Median price$0.5619
Average price$0.5473
Largest weekly change+37.3% (Jun 19, 2024)
Weeks tracked213
Tracking sinceSep 7, 2022

Price History

1W

0.0%

1M

+4.7%

3M

+15.9%

6M

+15.7%

1Y

-9.8%

3Y

-4.1%

5Y

N/A

All

-13.7%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 14% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, manufactured by NorthStar Rx LLC, is $0.5290 per EA (NDC 16714053401), effective Sep 30, 2026.

How has the price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB changed over time?

Over the history we have for it, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has declined 13.7%. It has been tracked across 213 weekly CMS publications since Sep 7, 2022.

What are the highest and lowest recorded NADAC prices for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?

Since Sep 7, 2022, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has ranged from a low of $0.4258 (May 22, 2024) to a high of $0.6267 (Jun 14, 2023), with a median of $0.5619 per EA.

Are there cheaper alternatives to EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?

Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, is $0.4572 per EA — about 14% below EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB.

Who manufactures EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?

EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB (NDC 16714053401) is labeled by NorthStar Rx LLC, and CMS classifies it as a generic product.